A new trading day began on Tuesday, with Biogen Inc (NASDAQ: BIIB) stock price down -3.95% from the previous day of trading, before settling in for the closing price of $185.63. BIIB’s price has ranged from $110.04 to $190.20 over the past 52 weeks.
Healthcare Sector giant saw their annual sales slid by -18.66% over the last five years. Meanwhile, its annual earnings per share averaged -9.10%. With a float of $146.44 million, this company’s outstanding shares have now reached $146.70 million.
Biogen Inc (BIIB) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – General Industry. The insider ownership of Biogen Inc is 0.18%, while institutional ownership is 92.11%. The most recent insider transaction that took place on Sep 02 ’25, was worth 69,045. In this transaction Head of Development of this company sold 517 shares at a rate of $133.55, taking the stock ownership to the 5,772 shares. Before that another transaction happened on Sep 02 ’25, when Company’s Officer proposed sale 517 for $133.55, making the entire transaction worth $69,045.
Biogen Inc (BIIB) Earnings and Forecasts
In its latest quarterly report, released on 12/31/2024, the company reported earnings of 3.44 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of 3.52 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.10% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.42% during the next five years compared to -18.66% drop over the previous five years of trading.
Biogen Inc (NASDAQ: BIIB) Trading Performance Indicators
Here are Biogen Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.70. Likewise, its price to free cash flow for the trailing twelve months is 11.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 10.97, a number that is poised to hit 1.70 in the next quarter and is forecasted to reach 15.17 in one year’s time.
